Ken Griffin Fate Therapeutics Inc Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 15,800 shares of FATE stock, worth $27,018. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,800

Previous 3,700 327.03%

Holding current value

$27,018

Previous $12,000 116.67%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.61 - $3.35 $161,289 - $335,603	100,180 Added 2.34%	4,382,257 $7.23 Million
Q3 2024 Nov 14, 2024	SELL	$3.12 - $5.57 $642,560 - $1.15 Million	-205,949 Reduced 4.59%	4,282,077 $15 Million
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $4.42 Million - $9.6 Million	1,356,500 Added 43.32%	4,488,026 $14.7 Million
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $1.65 Million - $3.89 Million	465,318 Added 17.45%	3,131,526 $23 Million
Q4 2023 Feb 14, 2024	BUY	$1.65 - $3.94 $1.07 Million - $2.55 Million	646,576 Added 32.01%	2,666,208 $9.97 Million
Q3 2023 Nov 14, 2023	SELL	$2.02 - $5.04 $531,055 - $1.33 Million	-262,899 Reduced 11.52%	2,019,632 $4.28 Million
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $2.97 Million - $4.11 Million	623,759 Added 37.6%	2,282,531 $10.9 Million
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $1 Million - $2.63 Million	236,635 Added 16.64%	1,658,772 $9.46 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $10.1 Million - $24.5 Million	1,028,798 Added 261.56%	1,422,137 $14.3 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $864,954 - $1.48 Million	41,110 Added 11.67%	393,339 $8.82 Million
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $1.2 Million - $2.87 Million	-67,693 Reduced 16.12%	352,229 $8.73 Million
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $7.35 Million - $14.9 Million	247,765 Added 143.92%	419,922 $16.3 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $324,116 - $435,903	-6,775 Reduced 3.79%	172,157 $10.1 Million
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $30.1 Million - $48.6 Million	-507,552 Reduced 73.94%	178,932 $10.6 Million
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $10.5 Million - $14.4 Million	-155,665 Reduced 18.48%	686,484 $59.6 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $19.2 Million - $31.3 Million	-266,491 Reduced 24.04%	842,149 $69.4 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $56.5 Million - $150 Million	-1,482,930 Reduced 57.22%	1,108,640 $101 Million
Q3 2020 Nov 16, 2020	SELL	$30.41 - $40.5 $20.9 Million - $27.8 Million	-685,907 Reduced 20.93%	2,591,570 $104 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $20.4 Million - $35.5 Million	1,008,949 Added 44.48%	3,277,477 $112 Million
Q1 2020 May 15, 2020	BUY	$17.28 - $31.88 $24.6 Million - $45.4 Million	1,422,711 Added 168.21%	2,268,528 $50.4 Million
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $3.64 Million - $5.63 Million	271,692 Added 47.32%	845,817 $16.6 Million
Q3 2019 Nov 14, 2019	SELL	$15.47 - $22.5 $4.57 Million - $6.65 Million	-295,664 Reduced 33.99%	574,125 $8.92 Million
Q1 2019 May 15, 2019	SELL	$13.15 - $18.71 $4.85 Million - $6.9 Million	-368,653 Reduced 29.77%	869,789 $0
Q4 2018 Feb 14, 2019	BUY	$11.48 - $16.98 $5.2 Million - $7.7 Million	453,196 Added 57.71%	1,238,442 $15.9 Million
Q3 2018 Nov 13, 2018	BUY	$8.75 - $16.29 $5.93 Million - $11 Million	677,366 Added 627.89%	785,246 $0
Q2 2018 Aug 10, 2018	BUY	$9.16 - $13.48 $988,180 - $1.45 Million	107,880 New	107,880 $0
Q1 2018 May 11, 2018	SELL	$6.3 - $13.77 $65,331 - $142,794	-10,370 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$3.94 - $6.64 $40,857 - $68,856	10,370	10,370 $63,000

Others Institutions Holding FATE

# of Institutions

167

Shares Held

101M

Call Options Held

41.3K

Put Options Held

15.9K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $166M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account